Articles tagged with Colorectal Cancer
Researchers have identified a consistent microbial signature of colorectal cancer by reanalyzing nearly 6,800 gut microbiome profiles. The study found that microbes detected in stool samples reflect microbes found directly within colorectal tumours.
Research reveals two distinctly different microbial worlds in colorectal cancer, one for left- and right-sided tumors. The study found that the mucosal microbiome varies dramatically depending on tumor location, opening possibilities for microbiome-based diagnostics and personalized treatment approaches.
This review highlights the regulatory roles of m6A in colorectal cancer, integrating oncogenic signaling and metabolic pathways. Key regulators include METTL3, METTL14, FTO, ALKBH5, and IGF2BP families, which control tumor growth, metastasis, immune evasion, and therapy resistance.
A recent study found associations between early-onset colorectal cancer and male sex, Hispanic ethnicity, high birthweight, maternal birthplace, and paternal age. The study suggests that these factors may contribute to the rising incidence of early-onset colorectal cancer.
A cross-sectional study found that colorectal cancer screening participation increased after an organized population screening program, but socioeconomic disparities remained. Younger age groups, single households, and lower-income individuals still lag behind in screening uptake.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
A cross-sectional study found early age–onset colorectal cancer patients with improved overall survival but delayed treatment experienced worse outcomes. Language barriers may be a modifiable risk factor contributing to these delays.
Researchers at UT MD Anderson Cancer Center have made significant advances in understanding cancer biology, developing AI-powered atlas of tertiary lymphoid structures as prognostic biomarkers, and uncovering drivers of resistance to KRAS inhibitors. Additionally, they have discovered a molecular pathway that drives stressed cells to b...
A novel deep learning framework integrates high-resolution pathology images with spatial transcriptomics and proteomics to reveal complex intra-tumor heterogeneity in colorectal cancer. The approach identifies distinct molecular subtypes that correlate with immune cell infiltration patterns.
Researchers found that CTHRC1, a secreted protein in tumor microenvironment, promotes colorectal cancer growth by limiting effective immune surveillance. The study suggests targeting CTHRC1 as a promising new strategy for future therapies.
The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.
A Phase 3 trial showed a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination. The treatment improved median progression-free survival and overall survival, with nearly 75% of patients alive at 18 months.
Researchers at the University of Jyväskylä have developed an AI model that can analyze colorectal cancer samples more efficiently and accurately predict the functioning of the cells' DNA repair mechanism. This could lead to shorter diagnosis times, reduced costs, and improved analysis accuracy.
Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.
The American Cancer Society has updated its guidelines for colorectal cancer screening, introducing blood-based and at-home stool testing options to increase accessibility. The new recommendations aim to close the screening gap and detect more cancers at an earlier stage, with a focus on underserved populations.
The American Cancer Society has endorsed two new types of stool tests and recommends limiting the use of blood tests for colorectal cancer screening. The guidelines aim to encourage people to get screened while improving detection rates.
A study by Harvard T.H. Chan School of Public Health found that gut microbiome alterations persist even after adenoma removal, increasing the risk of colorectal cancer. The researchers discovered that diet and physical activity were closely tied to CRC-associated gut microbes, suggesting lifestyle habits may contribute to sustained risk.
A new study found that an intervention increasing colorectal cancer screening had similar effects across Hispanic, non-Hispanic Black, and non-Hispanic White patients. Overall completion rates remained lower for Black patients despite the intervention.
Researchers at UT MD Anderson Cancer Center have uncovered genetic and cell-state adaptive mechanisms that drive resistance to KRAS inhibitors in patients with KRAS-mutant colorectal cancer. Targeting early inflammatory responses by adding TBK1 blockade may be a promising combination strategy to overcome treatment resistance.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
A nationwide implementation of a uniform multimodal prehabilitation program significantly reduced complication rates and length of hospital stay among patients undergoing colorectal cancer surgery. This study highlights the benefits of standardized preoperative care in improving patient outcomes.
Patients treated at NAPRC-accredited hospitals were less likely to have cancer cells remaining after surgery, associated with lower recurrence rates. These hospitals also delivered more comprehensive presurgical testing and improved surgical outcomes.
Researchers found a sustained reduction in colorectal cancer incidence and death associated with single flexible sigmoidoscopy screening, particularly in men. The study suggests that this screening method can provide long-lasting benefits beyond the usual 15-year screening age range.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Researchers at Mount Sinai have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer. The approach, which restores communication between key immune cells, achieved up to 100% tumor clearance in some models.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
Researchers discovered CLCA4 suppresses CSC properties and enhances anti-PD-1 immunotherapy, halting tumor growth and immune suppression in colorectal cancer. CLCA4 overexpression also reshaped the tumor immune microenvironment, sensitizing tumors to anti-PD-1 therapy.
A recent study found an association between early-onset colorectal cancer and exposure to certain pesticides, particularly picloram. However, experts warn that further investigations are needed to confirm causality and establish a biological mechanism.
Researchers at Vanderbilt University Medical Center discovered that enterotoxigenic Bacteroides fragilis reshapes intestinal cell metabolism to support its growth, causing diseases like diarrhea and colorectal cancer. The study provides new possibilities for intervention by targeting metabolic interactions between host and microbes.
Cancer cases are on the rise among younger adults in England, with a significant increase in bowel and ovarian cancer rates. The study found that excess weight is a key contributor, but it's unlikely to fully explain this trend, as trends in risk factors such as smoking and diet have been stable or improving over the past decade.
Researchers found that a newer stool-based screening test, FIT-DNA, increased completion rates among participants from community health centers. However, follow-up colonoscopy tests remained low, highlighting the need for continued support and access to diagnostic services.
A study finds that rectal cancer mortality is increasing rapidly among adults under 45, with Hispanic and Western US populations experiencing the steepest rises. The study calls for earlier screening and increased awareness to combat this growing trend.
Colorectal cancer incidence is rising among young individuals in Switzerland, with cancers occurring before age 50 accounting for 6.1% of all cases. The study highlights the importance of awareness and earlier screening to address this trend.
A nationwide study reveals that individuals with lower educational attainment are more likely to die from colorectal cancer at a younger age. The disparity in young-onset CRC mortality nearly doubled over the past three decades among those with 12 years or less education compared to those with 16 or more years of education.
Researchers found that sleep deprivation alters the composition of gut microbiota, leading to worse cancer progression and reduced effectiveness of chemotherapy. The study highlights the importance of maintaining a healthy microbiome through good sleep and diet.
Research from Lund University found a link between male infertility and an increased risk of developing colorectal and thyroid cancer. Men who underwent assisted reproduction techniques, such as ICSI, were more likely to develop these cancers.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
The study projects that cancer rates in Canada will be high in 2026, with declines seen in some cancers like colorectal and leukemia. However, death rates from pancreatic cancer are increasing.
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
Adults aged 75 or older without adenoma on prior colonoscopy have lower risk of subsequent colorectal cancer and CRC death. Despite this, those with prior adenoma may consider deprioritizing surveillance colonoscopy relative to other health concerns.
A national study found that unmet health-related social needs are associated with lower colorectal cancer screening rates, particularly among adults aged 50-64. Addressing these needs may support age-specific strategies to improve screening rates.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
A new blood-based biomarker has been discovered to help identify individuals at higher risk of developing cancer in people with Lynch Syndrome. The biomarker uses immune signatures detected in blood samples to provide unique characteristics that can detect cancer risk, allowing for early detection and personalized surveillance.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.
A phase III clinical trial established a new treatment standard for patients with stage III colon cancer and deficient DNA mismatch repair. Immunotherapy drug atezolizumab showed significant benefits when added to chemotherapy, lowering the risk of cancer recurrence by 50%.
A legal petition has been filed with the USDA urging them to require warning labels on processed meat and poultry products due to their link to colorectal cancer. The Physicians Committee for Responsible Medicine argues that these products should be labeled as potentially carcinogenic despite passing inspection.
The event provided free blood pressure, glucose, and cholesterol screenings, as well as colorectal cancer risk assessments with take-home test kits. Families also participated in interactive health education activities and received CPR education.
Epigenetic modifiers targeting histone acetylation, methylation, and phosphorylation show significant preclinical promise in CRC. Combination strategies and novel degraders offer pathways to overcome resistance, including PROTACs targeting KDM3A/B that eliminate cancer stem cells via Wnt/β-catenin inhibition.
Researchers at Trinity College Dublin and their colleagues are developing a simple, high-accuracy blood test to detect bowel cancer. The CASPDx CRC test aims to transform cancer outcomes by moving screening away from invasive methods.
The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.
A decrease in colorectal cancer incidence was observed among individuals with negative screening colonoscopy results, particularly men, suggesting risk-based follow-up strategies. Nonadherence to scheduled colonoscopies increased the risk of CRC, highlighting the need for targeted interventions to improve early detection.
Researchers discovered that migration and invasion inhibitory protein (MIIP) suppresses colorectal cancer progression by preventing immune cells from adopting tumor-supportive behaviors. MIIP reduces cancer cell migration, invasion, and metastasis by interrupting an immune feedback loop involving STING, NFκB2, and IL-10.
A cross-sectional analysis found significant delays in treatment initiation for early-onset colorectal cancer in all-urban populations, with young male, Asian or Pacific Islander, Black, or Hispanic patients disproportionately affected. These delays, exceeding 90 days, challenge assumptions of uniformly timely access in urban settings.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
The King Center for Lynch Syndrome will advance research, outreach, education, and patient care for Lynch syndrome, a hereditary condition affecting 1 in 279 individuals. The center will provide cutting-edge research, life-long comprehensive care, and increased awareness for patients and families affected by Lynch syndrome.
Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.